T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy that has
historically been associated with a very poor prognosis. Nevertheless, despite a lack of …

Improved personalized adjustment of primary therapy to the perceived risk of relapse by
using new prognostic markers for treatment stratification may be beneficial to patients with …

Purpose Minimal residual disease (MRD) and genetic abnormalities are important risk
factors for outcome in acute lymphoblastic leukemia. Current risk algorithms dichotomize …

Improvements in risk-directed treatment and supportive care, together with increased
reliance on both national and international collaborative studies, have made childhood …

Background High hyperdiploidy is the most common genetic subtype of childhood acute
lymphoblastic leukaemia and is associated with a good outcome. However, some patients …

Incorporating genetics into risk-stratification for treatment of childhood B-progenitor acute
lymphoblastic leukaemia (B-ALL) has contributed significantly to improved survival. In about …

In childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL), cytogenetic
abnormalities remain important diagnostic and prognostic tools. A number of well …

Background Adjustment of mercaptopurine and methotrexate maintenance therapy of acute
lymphoblastic leukaemia by leucocyte count is confounded by natural variations. Cytotoxicity …

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. While there are
a number of well‐recognized prognostic biomarkers at diagnosis, the most powerful …

Acute lymphoblastic leukaemia (ALL) occurs in approximately 1: 1500 children and is less
frequently found in adults. The most common immunophenotype of ALL is the B cell lineage …